The standard therapy for pre-treated advanced or metastatic non-small cell lung cancer that is not squamous cell carcinoma is docetaxel. The brand name for docetaxel is Taxotere™ . In this study, we are investigating how the test substance SGN-B6A works, whether it is effective and safe and whether it works better than the standard treatment.
Aim of the study
The standard therapy for pre-treated advanced or metastatic non-small cell lung cancer that is not squamous cell carcinoma is docetaxel. The brand name for docetaxel is Taxotere™ . In this study, we are investigating how the test substance SGN-B6A works, whether it is effective and safe and whether it works better than the standard treatment.
Who can take part?
Participants with previously treated non-small cell lung cancer
Procedure
If you decide to participate, you will be randomly assigned to one of 2 groups and will receive the investigational drug SGN-B6A or docetaxel. Both preparations are administered into a vein in the arm (intravenously/i.v.). We will invite you to study visits twice within a study cycle if you are receiving SGN-B6A, or once if you are receiving docetaxel. A visit takes about 1 to 2 hours. Your participation in this study can last up to 5 years.
Compensation
Original study name
A randomized, open-label, phase III study evaluating SGN-B6A versus docetaxel in adult participants with previously treated non-small cell lung cancer
BASEC number
2023-01601
Sponsors